Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Archita Sharma,Dhavan Sharma,Feng Zhao
DOI: https://doi.org/10.1002/adhm.202300556
IF: 10
2023-06-14
Advanced Healthcare Materials
Abstract:Impaired wound healing after trauma, disorders, and surgeries impact millions of people globally every year. Dysregulation in orchestrated healing mechanisms and underlying medical complications make chronic wound management extremely challenging. Besides standard‐of‐care treatments including broad spectrum antibiotics and wound‐debridement, novel adjuvant therapies have been clinically tested and commercialized. These include topical agents, skin substitutes, growth factor delivery, and stem cell therapies. With a goal to overcome factors playing pivotal role in delayed wound healing, researchers are exploring novel approaches to elicit desirable healing outcomes in chronic wounds. Although recent innovations in wound care products, therapies, and devices have been extensively reviewed in past, a comprehensive review summarizing their clinical outcomes is surprisingly lacking. Herein, we have reviewed the commercially available wound care products and their performance in clinical trials to provide a statistically comprehensive understanding of their safety and efficacy. The performance and suitability of various commercial wound care platforms, including xenogeneic and allogenic products, wound care devices, and novel biomaterials, have been discussed for chronic wounds. The current clinical evaluation will provide a comprehensive understanding of the benefits and drawbacks of the most‐recent approaches and will enable researchers and healthcare providers to develop next‐generation technologies for chronic wound management. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?